DEFA14A 1 sbph-defa14a_20190710.htm DEFA14A sbph-defa14a_20190710.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )

 

 

Filed by the Registrant 

Filed by a Party other than the Registrant 

 

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Under Rule 14a-12

Spring Bank Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

1)

Title of each class of securities to which transaction applies:

 

 

2)

Aggregate number of securities to which transaction applies:

 

 

3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

4)

Proposed maximum aggregate value of transaction:

 

 

5)

Total fee paid:

 

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

 

1)

Amount previously paid:

 

 

2)

Form, Schedule or Registration Statement No:

 

 

3)

Filing party:

 

 

4)

Date Filed:

 

 

 

 

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on July 10, 2019.

 

 

 

SPRING BANK PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

 

SPRING BANK PHARMACEUTICALS, INC.

35 PARKWOOD DRIVE, SUITE 210

HOPKINTON, MA 01748

Meeting Information

Meeting Type:Annual Meeting

For holders as of:May 20, 2019

Date:   July 10, 2019Time:  8:30 a.m. EDT

Location:  Spring Bank Pharmaceuticals, Inc.

   35 Parkwood Drive, Suite 210

   Hopkinton, MA 01748

 

 

You are receiving this communication because you hold shares in the company named above.

 

This is not a ballot. You cannot use this notice to vote these shares.  This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

 

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

E80543-P25670

 

 

See the reverse side of this notice to obtain proxy materials and voting instructions.

 


Before You Vote

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT10-K WRAP

How to View Online:

Have the information that is printed in the box marked by the arrow -> XXXX XXXX XXXX XXXX     (located on the

following page) and visit: www.proxyvote .com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for

requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET:www.proxyvote.com

2) BY TELEPHONE:  1-800-579-1639

3) BY E-MAIL*:sendmaterial@proxyvote.com

 

*  If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow -> XXXX XXXX XXXX XXXX      (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 26, 2019 to facilitate timely delivery.

 

 

How To Vote

Please Choose One of the Following Voting Methods

Vote In Person:  Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box

 

marked by the arrow ->  XXXX XXXX XXXX XXXX     located on the following page) available and follow the instructions.

 

E80544-P25670

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 


E80545-P25670

 

Voting Items

 

The Board of Directors recommends you vote

FOR all the nominees listed and FOR Proposal 2.

 

 

1.

Election of the following nominees as Class I directors of Spring Bank Pharmaceuticals, Inc., each to serve for a three-year term expiring at the 2022 Annual Meeting of Stockholders:

 

 

01)   Timothy Clackson, Ph.D.

02)   Pamela Klein, M.D.

 

2.Ratification of the appointment of RSM US LLP as Spring Bank Pharmaceuticals, Inc.'s independent registered public accounting firm

for the year ending December 31, 2019.